NDM-1 (cont.)

Medical Author:
Medical Editor:

What is the prognosis for a person infected with NDM-1 producing bacteria?

NDM-1 infections can be successfully treated if they are identified early and if colistin or other appropriate agents are used promptly. As stated above, antibiotic sensitivity testing is standard in clinical laboratories and can be used to identify carbapenem-resistant strains and to guide antibiotic therapy. However, antibiotic sensitivity testing usually takes two days because the bacteria must be cultured in the laboratory.

Can infections with bacteria containing NDM-1 be prevented?

Comment on this

The risk of person-to-person spread of NDM-1 infection can be reduced by practicing good hand hygiene. This includes washing or disinfecting hands after using the bathroom and before preparing food. In hospitals, patients with suspected NDM-1 infections should be placed in a private room and cover gowns and gloves should be used by health-care personnel. Other barrier methods should be used if contamination is likely (for example, eye protection if splashing is possible). Strict hand hygiene should be observed. Hospitals should ensure that their laboratories are equipped to test for carbapenem resistance and hospital infection-control programs should review resistance patterns regularly.

To reduce the risk that NDM-1 will develop in bacteria, it is important to use existing antibiotics wisely. Carbapenem antibiotics should only be used when bacteria are resistant to older agents. Antibiotics should always be dosed appropriately.

Where can people find more information about NDM-1 producing bacteria?

More information about NDM-1 is available from the following sites:

Centers for Disease Control and Prevention
"Detection of Enterobacteriaceae Isolates Carrying Metallo-Beta-Lactamase --- United States, 2010." http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5924a5.htm

Centers for Disease Control and Prevention
"Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities." <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5810a4.htm>.

Medically reviewed by Robert Cox, MD; American Board of Internal Medicine with subspecialty in Infectious Disease

REFERENCES:

Kumarasamy, K.K., M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, et al. "Emergence of a New Antibiotic Resistance Mechanism in India, Pakistan, and the UK: A Molecular, Biological, and Epidemiological Study." Lancet Infect Dis 10 (2010): 597-602.

United States. Centers for Disease Control and Prevention. "Detection of Enterobacteriaceae Isolates Carrying Metallo-Beta-Lactamase --- United States, 2010." MMWR 59.24 (2010): 750. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5924a5.htm>.

United States. Centers for Disease Control and Prevention. "Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities." MMWR 58.10 Mar. 20, 2009: 256-260. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5810a4.htm>.


Medically Reviewed by a Doctor on 1/16/2014

Patient Comments

Viewers share their comments

NDM-1 - Signs and Symptoms Question: What signs and symptoms did you experience with a diagnosed NDM-1-related infection?
NDM-1 - Treatment Question: What treatments or medications did you receive for an infection caused by NDM-1?
NDM-1 - Prevention Question: In what ways do you prevent the risk of an infection with bacteria containing NDM-1?